SNGX Soligenix Inc.

1.44
-0.04  -3%
Previous Close 1.48
Open 1.48
Price To Book 24
Market Cap 37,120,941
Shares 25,778,431
Volume 508,608
Short Ratio
Av. Daily Volume 534,640
Stock charts supplied by TradingView

NewsSee all news

  1. Soligenix Announces Recent Accomplishments And Year-End 2019 Financial Results

    PRINCETON, N.J., March 30, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  2. Soligenix and University of Hawaiʻi at Mānoa Initiate Work on Novel Coronavirus Vaccine for COVID-19

    PRINCETON, N.J., March 23, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  3. Soligenix, Inc. Impresses With Statistically Significant Topline Phase 3 Data From SGX301 FLASH Trial; Targets $250 Million CTCL Patient Market

    New York, New York--(Newsfile Corp. - March 20, 2020) - Soligenix, on Thursday, announced positive topline data for its lead CTCL drug candidate, SGX301. The published data demonstrated statistically significant efficacy

  4. Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma

    PRINCETON, N.J., March 19, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  5. Soligenix Shows Pipeline Depth From Heat Stabilization Technology For Filovirus Vaccine Platform; Eyes Remain Focused On SGX301 Data Release

    Soligenix, on Thursday February 27th, gave the market some more good news. This time the company highlighted data from its ongoing collaboration with the University of Hawai’i at Manoa (UHM) and Hawaii

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial complete.
SGX201
Radiation Enteritis
Phase 3 top-line data met primary endpoint - March 19,2020. Cycle 2 data due June 2020.
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Phase 3 top-line data due 4Q 2020.
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer
Phase 3 dependent on funding.
SGX203
Pediatric Crohn’s Disease
Phase 1c trial initiation announced December 12, 2019.
RiVax
Ricin toxin vaccine

Latest News

  1. Soligenix Announces Recent Accomplishments And Year-End 2019 Financial Results

    PRINCETON, N.J., March 30, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  2. Soligenix and University of Hawaiʻi at Mānoa Initiate Work on Novel Coronavirus Vaccine for COVID-19

    PRINCETON, N.J., March 23, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  3. Soligenix, Inc. Impresses With Statistically Significant Topline Phase 3 Data From SGX301 FLASH Trial; Targets $250 Million CTCL Patient Market

    New York, New York--(Newsfile Corp. - March 20, 2020) - Soligenix, on Thursday, announced positive topline data for its lead CTCL drug candidate, SGX301. The published data demonstrated statistically significant efficacy

  4. Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma

    PRINCETON, N.J., March 19, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  5. Soligenix Shows Pipeline Depth From Heat Stabilization Technology For Filovirus Vaccine Platform; Eyes Remain Focused On SGX301 Data Release

    Soligenix, on Thursday February 27th, gave the market some more good news. This time the company highlighted data from its ongoing collaboration with the University of Hawai’i at Manoa (UHM) and Hawaii

  6. Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform

    PRINCETON, N.J., Feb. 27, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  7. FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning

    PRINCETON, N.J., Feb. 13, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  8. Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas

    PRINCETON, N.J., Feb. 11, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  9. Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis

    PRINCETON, N.J., Feb. 3, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  10. Soligenix to Present at the 22nd Annual BIO CEO & Investor Conference

    PRINCETON, N.J., Jan. 30, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  11. Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  12. Soligenix to Receive $850,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., Dec. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  13. CORRECTION FROM SOURCE: Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 13, 2019) - This news release has been corrected to add legal disclaimers. As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how

  14. Major Milestones for Soligenix Bring 2019 to a Strong Close

    New York, New York--(Newsfile Corp. - December 11, 2019) - As the end of the year's fourth quarter comes to a close, CEO3in60 highlights how Soligenix (NASDAQ:SNGX) has achieved multiple milestones across the

  15. Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

    PRINCETON, N.J., Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  16. Soligenix to Present at the PCG Spotlight Series Conference

    PRINCETON, N.J., Nov. 18, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  17. Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results

    PRINCETON, N.J., Nov. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  18. Soligenix to Present at the 25th Annual BIO-Europe International Partnering Conference

    PRINCETON, N.J., Nov. 6, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  19. Here's Why Soligenix Inc.'s SGX301 and SGX942 Can Change the CTCL and Oral Mucositis Treatment Landscape In A Matter of Months (NASDAQ: SNGX)

    Soligenix stock turns green ahead of two potential near-term catalysts. SGX301 and SGX942 late-stage data sets up company for strong 2020. Soligenix Inc. (NASDAQ:SNGX) stock has been enjoying upward momentum as data

  20. Video Report: Soligenix Inc. Bringing Two Catalysts Into View; SGX301 and SGX942 Can Change The CTCL and Oral Mucositis Treatment Landscape (NASDAQ: SNGX)

    Soligenix Inc. is in an enviable position of being the beneficiary of positive interim data from its two late-stage trials. And, if the topline data expected in the next 6-9 months can confirm interim analyses,

  21. Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer

    Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ:SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head

  22. Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada

    PRINCETON, N.J., Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  23. Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning

    PRINCETON, N.J., Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  24. Soligenix Appoints Jonathan Guarino as Chief Financial Officer

    PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  25. Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

    PRINCETON, N.J., Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases

  26. Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

    PRINCETON, N.J., Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases